PEPSINOGEN-C IS A NEW PROGNOSTIC MARKER IN PRIMARY BREAST-CANCER

被引:36
作者
VIZOSO, F
SANCHEZ, LM
DIEZITZA, I
MERINO, AM
LOPEZOTIN, C
机构
[1] UNIV OVIEDO,FAC MED,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN
[2] HOSP JOVE,SERV CIRUGIA GEN & ANAT PATOL,GIJON,FRANCE
关键词
D O I
10.1200/JCO.1995.13.1.54
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Here we evaluate in breast cancer patients the prognostic value of pepsinogen C, a proteolytic enzyme involved in the digestion of proteins in the stomach that is also synthesized by a significant percentage of breast carcinomas. Patients and Methods: Pepsinogen C expression was examined by immunoperoxidase staining in a series of 243 breast cancer tissue sections, and results obtained were quantified using the HSCORE system, which considers both the intensity and the percentage of cells staining at each intensity. Evaluation of the prognostic value of pepsinogen C was performed retrospectively in corresponding patients by multivariate analysis that took into account conventional prognostic factors. The mean follow-up period was 48.5 months. Results: A total of 113 carcinomas (46.5%) stained positively for this proteinase, but there were clear differences among them with regard to the intensity and percentage of stained cells. Pepsinogen C values were significantly higher in well differentiated (grade I, 89.1) and moderately differentiated (grade II, 88.5) tumors than in poorly differentiated (grade III, 27.7) tumors (P < .001). Similarly, significant differences in pepsinogen C content were found between estrogen receptor (ER) positive tumors and ER-negative tumors (85.9 v 41.2, respectively; P < .05), Moreover, results indicated that low pepsinogen C content predicted shorter relapse-free survival duration and overall survival duration (P < .0001). Separate Cox multivariate analysis for relapse free survival and overall survival in subgroups of patients as defined by node status showed that pepsinogen C expression was the strongest factor to predict both relapse-free survival and overall survival in node-positive patients (P < .0001 for both) and node-negative patients (P < .005 and P < .01, respectively). Conclusion: Pepsinogen C is a new prognostic factor for early recurrence and death in both node-positive and node-negative breast cancer, In addition, and in contrast to most studies that concern the prognostic significance of proteolytic enzymes in cancer, pepsinogen C production by breast cancer cells is associated with lesions of favorable evolution.
引用
收藏
页码:54 / 61
页数:8
相关论文
共 39 条
[31]  
SANCHEZ LM, 1992, J BIOL CHEM, V267, P24725
[32]   CATHEPSIN-D IN BREAST SECRETIONS FROM WOMEN WITH BREAST-CANCER [J].
SANCHEZ, LM ;
FERRANDO, AA ;
DIEZITZA, I ;
VIZOSO, F ;
RUIBAL, A ;
LOPEZOTIN, C .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :1076-1081
[33]  
SAPPINO AP, 1987, CANCER RES, V47, P4043
[34]   REGULATION OF PROGESTERONE-BINDING BREAST CYST PROTEIN GCDFP-24 SECRETION BY ESTROGENS AND ANDROGENS IN HUMAN BREAST-CANCER CELLS - A NEW MARKER OF STEROID ACTION IN BREAST-CANCER [J].
SIMARD, J ;
DAUVOIS, S ;
HAAGENSEN, DE ;
LEVESQUE, C ;
MERAND, Y ;
LABRIE, F .
ENDOCRINOLOGY, 1990, 126 (06) :3223-3231
[35]   LYSOSOMAL CATHEPSIN-B - CORRELATION WITH METASTATIC POTENTIAL [J].
SLOANE, BF ;
DUNN, JR ;
HONN, KV .
SCIENCE, 1981, 212 (4499) :1151-1153
[36]  
SPYRATOS F, 1989, LANCET, V8672, P1115
[37]   SEMINAL PEPSINOGEN-C IS NOT IDENTICAL WITH, BUT IS VERY SIMILAR TO GASTRIC PEPSINOGEN-C [J].
SZECSI, PB ;
KOCH, C ;
FOLTMANN, B .
FEBS LETTERS, 1988, 238 (01) :101-104
[38]   CATHEPSIN-D AND PROGNOSIS IN BREAST-CANCER [J].
TANDON, AK ;
CLARK, GM ;
CHAMNESS, GC ;
CHIRGWIN, JM ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (05) :297-302
[39]  
Vaitukaitis J L, 1981, Methods Enzymol, V73, P46